PMID- 30241119
OWN - NLM
STAT- MEDLINE
DCOM- 20191007
LR  - 20191007
IS  - 1066-2936 (Print)
IS  - 1066-2936 (Linking)
VI  - 45
IP  - 4
DP  - 2018 Jul-Aug
TI  - Evaluation of hyperbaric oxygen effects on slow coronary flow patients using 
      gated myocardial perfusion imaging tomography.
PG  - 403-409
AB  - Hyperbaric oxygen (HBO2) is widely used in clinical settings for many disease 
      treatments. To investigate the potential effects of hyperbaric oxygen on patients 
      with slow coronary flow (SCF) we retrospectively analyzed 98 patients who were 
      diagnosed with SCF by coronary artery angiography. Of these, 50 patients received 
      conventional treatment only (control group; the other 48 patients received 
      hyperbaric oxygen treatment for four weeks in addition to the routine therapy 
      (HBO2 group). By using gated myocardial perfusion tomography examination before 
      and after treatment, we observed that 71 out of 148 (47.9%) subsegments of 
      injured myocardium improved in the control group, while 108 out of 151 (71.5%) 
      subsegments of injured myocardium improved in the HBO2 group (P ⟨ 0.05). 
      Furthermore, the peak filling rate (PFR), time of peak filling rate (TPFR) and 
      mean filling rate during the first one-third of the filling time (MFR/3) were all 
      significantly improved in HBO2-treated patients compared to those who received 
      conventional treatment only. However, we did not detect any significant effects 
      of only treatment on left ventricular end diastolic volume (LVEDV), left 
      ventricular end systolic volume (LVESV), nor on left ventricular ejection 
      fraction (LVEF). Our results indicate that hyperbaric oxygen therapy can be a 
      beneficial and effective medication to improve myocardial perfusion and left 
      ventricular diastolic function in SCF patients.
CI  - Copyright(c) Undersea and Hyperbaric Medical Society.
FAU - Li, Yuan
AU  - Li Y
AD  - Department of Cardiology, The Fourth Hospital of Shijiazhuang, Shi Jia Zhuang, 
      Hebei Province, China.
FAU - Zhang, HuiPing
AU  - Zhang H
AD  - Department of Otolaryngology Heibei People's Hospital, Shi Jia Zhuang, Hebei 
      Province, China.
FAU - Hao, Ya-Feng
AU  - Hao YF
AD  - Department of Cardiology, The First hospital of Handan, Han Dan, Hebei Province, 
      China.
FAU - Liang, Yi
AU  - Liang Y
AD  - Department of Hyperbaric Oxygen, the Third Hospital of Hebei Medical University, 
      Shi Jia Zhuang, Hebei Province, China.
FAU - Wei, Ling-Ge
AU  - Wei LG
AD  - Department of Nuclear Medicine, the Third Hospital of Hebei Medical University, 
      Shi Jia Zhuang, Hebei Province, China.
FAU - Xu, Tong-Shun
AU  - Xu TS
AD  - Department of Cardiology, The Fourth Hospital of Shijiazhuang, Shi Jia Zhuang, 
      Hebei Province, China.
FAU - Wang, Tao
AU  - Wang T
AD  - Department of Cardiology, the Third Hospital of Hebei Medical University, Shi Jia 
      Zhuang, Hebei Province, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Undersea Hyperb Med
JT  - Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical 
      Society, Inc
JID - 9312954
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Flow Velocity
MH  - Blood Volume
MH  - Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography
MH  - Case-Control Studies
MH  - Coronary Artery Disease/physiopathology/*therapy
MH  - Coronary Circulation/*physiology
MH  - Female
MH  - Humans
MH  - *Hyperbaric Oxygenation
MH  - Male
MH  - Middle Aged
MH  - Myocardial Perfusion Imaging/*methods
MH  - Retrospective Studies
MH  - Stroke Volume/physiology
MH  - Ventricular Dysfunction, Left/*therapy
OTO - NOTNLM
OT  - hyperbaric oxygen therapy
OT  - ocular variables
OT  - short-term effects
COIS- The authors of this paper declare no conflicts of interest exist with this 
      submission.
EDAT- 2018/09/22 06:00
MHDA- 2019/10/08 06:00
CRDT- 2018/09/22 06:00
PHST- 2018/09/22 06:00 [entrez]
PHST- 2018/09/22 06:00 [pubmed]
PHST- 2019/10/08 06:00 [medline]
PST - ppublish
SO  - Undersea Hyperb Med. 2018 Jul-Aug;45(4):403-409.